Conclusion: Conclusion: Results from the systematic review showed that the OTC misusing issues are both widespread worldwide and popular; vulnerable categories include adolescents and young adults, although real prevalence figures remain unknown, due to a lack of appropriate monitoring systems. Considering the potential, and at times serious, adverse effects associated with OTC misusing issues, healthcare professionals should be vigilant, and ad hoc preventative actions should be designed and implemented.
Dxm side effects
Across 52 first-hand reports, people mentioned a side effect 9 times (about 17 per 100 reports). The most common: brain fog, serotonin syndrome, blackouts. User reports show what people notice — they can't tell you whether Dxm is safe for you.
Reported side effects
In their own words
“DXM did nothing to me except for nausea and ugly feeling to be honest.”
“It [DXM] works great for me at low levels. I usually take 60-120mg a few days a week and it yas been incredibly helpful for my depression and anxiety.”
“I had chronic mild serotonin syndrome from dxm... It’s been 4 years sober, it’s taken years to feel somewhat normal.”
“I tried DXM but only got trivial results (could be because today is my first trying it in the form of delsym, which is time released).”
“I've used DXM in the past for its antidepressant effects - It ruins my cognition for the next day though.”
“I did some DXM even a week after my last curcumin dose and when I peaked I got brain zaps and OEVs just from a normal 10ml cough dose along with borderline panic attacks.”
Is Dxm safe? What the research covers
Conclusion: DXM had a significantly higher incidence of secondary surgical intervention. However, there was no difference regarding mortality and other safety outcomes between surgery and DXM for the patients with CSDH. Observational studies showed that DXM was associated with a lower risk of poor postoperative outcomes within hospital stay and had shorter duration of hospital stay, but the recurrence rate was lower in the surgery group.
Conclusion: The results of this meta-analysis showed that there was no difference in mortality, ICU admission rate, hospital stay, mechanical ventilation, or adverse events between MP and DXM in the treatment of COVID-19. The incidence of hyperglycemia with methylprednisolone was higher than that with dexamethasone.